CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities
Net (loss) income from operations	$ (1,571,720)	$ 523,877
Adjustments to reconcile net income from continuing operations to net cash provided by operating activities:
Depreciation and amortization	4,203,756	902,426
Gain on sale of Infusionz and select assets	(7,564,363)	0
Gain on sale of assets	0	(5,500)
Inventory write-offs	34,328	140,000
Bad debt expense	0	1,000
Accrued interest on note receivable from Bloomios	(141,635)	0
Amortization of senior security original issue discount	(455,450)	0
Uncollected transition fees from Bloomios	(428,500)	0
Non-controlling interest	(358,390)	0
Change in deferred tax asset	(515,089)	156,204
Shares issued for services	0	358,915
Shares issued for finder fee	1,770	33,740
Stock based compensation	3,126,472	1,940,651
Changes in assets and liabilities, net of acquired amounts
Accounts receivable	2,490,729	21,735
Inventory	2,293,866	(604,325)
Prepaid expenses and other assets	(28,090)	533,103
Operating lease payable	2,975	(17,062)
Accounts payable and accrued liabilities	2,488,065	731,726
Deferred revenue	(57,686)	85,030
Net cash provided by operating activities - Continuing Operations	3,521,038	4,801,520
Net cash used in operating activities - Discontinued Operations	0	(2,634,975)
Net cash provided by operating activities	3,521,038	2,166,545
Cash flows from investing activities
Acquisition of Lucky Tail	(3,012,327)	0
Acquisition of VitaMedica, Inc., net of cash acquired	(500,000)	(2,574,589)
Acquisition of New England Technology, Inc.	(2,085,390)	0
Acquisition of Cygnet	(1,050,000)	0
Acquisition of Interative Offers, net of cash acquired	0	(1,854,193)
Proceeds from the sale of Infusionz and selected assets	4,273,427	6,000
Acquisition of property and equipment	(278,683)	(5,649,100)
Net cash used in investing activities - Continuing Operations	(2,652,973)	(10,071,882)
Net cash (used in) provided by investing activities - Discontinued Operations		0
Net cash used in investing activities	(2,652,973)	(10,071,882)
Cash flows from financing activities
Repayment of notes payable	(470,168)	(150,000)
Repayment of SBA note payable	(254,804)	0
Repayment of the senior convertible notes payable	(6,307,775)	0
Payment on line of credit, net	(6,826,338)	0
Proceeds on note payable on building	3,000,000	0
Stock repurchase program	0	(1,975,888)
Repayment on note payable on building	(97,744)	0
Proceeds from issuance of convertible debt	2,650,000	0
Proceeds on note payable, related party	1,470,000	0
Net cash used in financing activities - Continuing Operations	(6,836,829)	(2,125,888)
Net cash (used in) provided by financing activities - Discontinued Operations	0	0
Net cash used in financing activities	(6,836,829)	(2,125,888)
Net decrease in cash - Continuing Operations	(5,968,764)	(7,396,250)
Net decrease in cash - Discontinued Operations	0	(2,634,975)
Cash, beginning of period	7,149,806	14,534,211
Cash, end of period	1,181,042	4,502,986
Supplemental cash flow disclosures
Interest paid	326,918	0
Income tax paid	0	0
Non-cash financing activities
Issuance of common stock for acquisition of Infusionz	0	1,764,876
Issuance of common stock for acquisition of VitaMedica	0	482,000
Issuance of debt for acquisition of VitaMedica	0	1,000,000
Liabilities assumed from acquisition of LuckyTail	0	0
Issuance of common stock for acquisition of E-Core	6,000,000	0
Liabilities assumed from acquisition of E-Core	(7,712,168)	0
Non-cash consideration received from Bloomios for the sale of Infusionz	18,000,000	0
Operating assets designated as held for sale	6,446,210	6,786,289
Liabilities assumed from acquisition of VitaMedica	0	$ (309,574)
Issuance of stock for acquisition of Interactive		4,000,000
Liabilities assumed from acquisition of Interactive	$ 0	$ (1,099,993)